ProPhase Labs, Inc. Revenue Recognition, Sales Returns, Reserve for Sales Returns
ProPhase Labs, Inc. (PRPH) reported Revenue Recognition, Sales Returns, Reserve for Sales Returns of $260.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Notes
us-gaap:RevenueRecognitionSalesReturnsReserveForSalesReturns · last filed 2018-11-14
- ProPhase Labs, Inc. revenue recognition, sales returns, reserve for sales returns for the quarter ending 2018-09-30 was -$183.00K.
- ProPhase Labs, Inc. revenue recognition, sales returns, reserve for sales returns for the quarter ending 2018-06-30 was -$9.00K.
- ProPhase Labs, Inc. revenue recognition, sales returns, reserve for sales returns for the quarter ending 2018-03-31 was $452.00K.
- ProPhase Labs, Inc. revenue recognition, sales returns, reserve for sales returns for fiscal 2016 was $1.20M.
| Period end | Revenue Recognition, Sales Returns, Reserve for Sales Returns 3 month | Revenue Recognition, Sales Returns, Reserve for Sales Returns 6 month | Revenue Recognition, Sales Returns, Reserve for Sales Returns 9 month | Revenue Recognition, Sales Returns, Reserve for Sales Returns 12 month |
|---|---|---|---|---|
| 2018-09-30 | -$183.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$192.00K derived: sum of 2 quarters · filed 2018-11-14 | $260.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-20 | $443.00K 10-Q · filed 2018-08-20 | ||
| 2018-03-31 | $452.00K 10-Q/A · filed 2018-08-20 | |||
| 2017-12-31 | $480.00K 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $1.20M 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |